{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:00:27Z","timestamp":1791907227227,"version":"4.3.4"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001794","name":"The University of Queensland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40262-025-01488-2","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T14:32:56Z","timestamp":1744900376000},"page":"655-689","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A Systematic Review of Pharmacokinetic Studies of Colistin and Polymyxin B in Adult Populations"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0221-2894","authenticated-orcid":false,"given":"Puteri Juanita","family":"Zamri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sazlyna Mohd Sazlly","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fekade Bruck","family":"Sime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Hafiz","family":"Abdul-Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"issue":"6","key":"1488_CR1","doi-asserted-by":"publisher","first-page":"105493","DOI":"10.1016\/j.ijantimicag.2020.105943","volume":"55","author":"J Xie","year":"2020","unstructured":"Xie J, Roberts JA, Lipman J, et al. Pharmacokinetic\/pharmacodynamic adequacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in critically ill, general ward and cystic fibrosis patient populations. Int J Antimicrob Agents. 2020;55(6):105493.","journal-title":"Int J Antimicrob Agents"},{"key":"1488_CR2","doi-asserted-by":"crossref","unstructured":"Avedissian SN, Liu J, Rhodes NJ, et al. A review of the clinical pharmacokinetics of polymyxin B. Antibiotics (Basel). 2019 Mar 22;8(1):31.","DOI":"10.3390\/antibiotics8010031"},{"key":"1488_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/2808203","volume":"2017","author":"S Busani","year":"2017","unstructured":"Busani S, Roat E, Serafini G, et al. The role of adjunctive therapies in septic shock by Gram negative MDR\/XDR infections. Can J Infect Dis Med Microbiol. 2017;2017:1\u20136.","journal-title":"Can J Infect Dis Med Microbiol."},{"issue":"12","key":"1488_CR4","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1007\/s00134-012-2695-9","volume":"38","author":"A Tabah","year":"2012","unstructured":"Tabah A, Koulenti D, Laupland K, et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med. 2012;38(12):1930\u201345.","journal-title":"Intensive Care Med"},{"key":"1488_CR5","unstructured":"U.S. Department of Health and Human Services. Antibiotic resistance threats in the United States, 2019. Atlanta (GA): U.S. Department of Health and Human Services; 2019."},{"key":"1488_CR6","doi-asserted-by":"crossref","unstructured":"Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America Guidance on the Treatment of AmpC \u03b2-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections. Clin Infect Dis. 2022 Jul 6;74(12):2089-2114.","DOI":"10.1093\/cid\/ciab1013"},{"issue":"1","key":"1488_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"BT Tsuji","year":"2019","unstructured":"Tsuji BT, Pogue JM, Zavascki AP,\u00a0 et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019 Jan;39(1):10-39.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"1488_CR8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10096-020-04053-w","volume":"40","author":"R Soman","year":"2021","unstructured":"Soman R, Bakthavatchalam YD, Nadarajan A, et al. Is it time to move away from polymyxins?: evidence and alternatives. Eur J Clin Microbiol Infect Dis. 2021 Mar;40(3):461-475.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1488_CR9","doi-asserted-by":"crossref","unstructured":"Ho S, Nguyen L, Trinh T, et al. Recognizing and Overcoming Resistance to New Beta-Lactam\/Beta-Lactamase Inhibitor Combinations. Curr Infect Dis Rep. 2019 Sep 9;21(10):39.","DOI":"10.1007\/s11908-019-0690-9"},{"issue":"5","key":"1488_CR10","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1586\/14787210.5.5.811","volume":"5","author":"A Kwa","year":"2007","unstructured":"Kwa A, Kasiakou SK, Tam VH, et al. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther. 2007 Oct;5(5):811-21.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"10","key":"1488_CR11","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1517\/14656566.2014.914172","volume":"15","author":"I Karaiskos","year":"2014","unstructured":"Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother. 2014;15(10):1351\u201370.","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"1488_CR12","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1021\/jm900999h","volume":"53","author":"T Velkov","year":"2010","unstructured":"Velkov T, Thompson PE, Nation RL, Li J. Structure--activity relationships of polymyxin antibiotics. J Med Chem. 2010 Mar 11;53(5):1898-916.","journal-title":"J Med Chem"},{"issue":"6","key":"1488_CR13","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.ijantimicag.2016.09.010","volume":"48","author":"TB Tran","year":"2016","unstructured":"Tran TB, Velkov T, Nation RL, et al. Pharmacokinetics\/pharmacodynamics of colistin and polymyxin B: are we there yet? Int J Antimicrob Agents. 2016 Dec;48(6):592-597.","journal-title":"Int J Antimicrob Agents"},{"key":"1488_CR14","doi-asserted-by":"crossref","unstructured":"Li J, Nation RL, Kaye KS. Polymyxin antibiotics: from laboratory bench to bedside. Advances in experimental medicine and biology. Vol 1145. Cham: Springer; 2019.","DOI":"10.1007\/978-3-030-16373-0"},{"issue":"7","key":"1488_CR15","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1128\/AAC.01733-10","volume":"55","author":"SM Garonzik","year":"2011","unstructured":"Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011 Jul;55(7):3284-94.","journal-title":"Antimicrob Agents Chemother"},{"key":"1488_CR16","doi-asserted-by":"crossref","unstructured":"Satlin MJ, Lewis JS, Weinstein MP, et al. Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing Position Statements on Polymyxin B and Colistin Clinical Breakpoints. Clin Infect Dis. 2020 Dec 3;71(9):e523-e529.","DOI":"10.1093\/cid\/ciaa121"},{"key":"1488_CR17","doi-asserted-by":"crossref","unstructured":"Forrest A, Garonzik SM, Thamlikitkul V, et al. Pharmacokinetic\/Toxicodynamic Analysis of Colistin-Associated Acute Kidney Injury in Critically Ill Patients. Antimicrob Agents Chemother. 2017 Oct 24;61(11):e01367-17.","DOI":"10.1128\/AAC.01367-17"},{"key":"1488_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71.","journal-title":"BMJ"},{"key":"1488_CR19","unstructured":"Covidence systematic review software. Melbourne (VIC): Veritas Health Innovation; 2022."},{"issue":"7","key":"1488_CR20","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40262-015-0236-8","volume":"54","author":"S Kanji","year":"2015","unstructured":"Kanji S, Hayes M, Ling A, et al. Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement. Clin Pharmacokinet. 2015 Jul;54(7):783-95.","journal-title":"Clin Pharmacokinet"},{"key":"1488_CR21","doi-asserted-by":"crossref","unstructured":"Kristoffersson AN, Rogn\u00e5s V, Brill MJE, et al. Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria. Clin Microbiol Infect. 2020 Dec;26(12):1644-1650.","DOI":"10.1016\/j.cmi.2020.03.016"},{"key":"1488_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.967412","volume":"13","author":"YL Xie","year":"2022","unstructured":"Xie YL, Jin X, Yan SS, et al. Population pharmacokinetics of intravenous colistin sulfate and dosage optimization in critically ill patients. Front Pharmacol. 2022 Aug 29;13:967412.","journal-title":"Front Pharmacol"},{"key":"1488_CR23","doi-asserted-by":"crossref","unstructured":"Leuppi-Taegtmeyer AB, Decosterd L, Osthoff M, et al. Multicenter Population Pharmacokinetic Study of Colistimethate Sodium and Colistin Dosed as in Normal Renal Function in Patients on Continuous Renal Replacement Therapy. Antimicrob Agents Chemother. 2019 Jan 29;63(2):e01957-18.","DOI":"10.1128\/AAC.01957-18"},{"issue":"5","key":"1488_CR24","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1093\/cid\/ciw839","volume":"64","author":"RL Nation","year":"2017","unstructured":"Nation RL, Garonzik SM, Thamlikitkul V, et al. Dosing guidance for intravenous colistin in critically-ill patients. Clin Infect Dis. 2017 Mar 1;64(5):565-571.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1488_CR25","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ijantimicag.2016.06.008","volume":"48","author":"I Karaiskos","year":"2016","unstructured":"Karaiskos I, Friberg LE, Galani L, et al. Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration. Int J Antimicrob Agents. 2016 Sep;48(3):337-41.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"1488_CR26","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1128\/AAC.00985-12","volume":"57","author":"M Karvanen","year":"2013","unstructured":"Karvanen M, Plachouras D, Friberg LE, et al. Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother. 2013 Jan;57(1):668-71.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1488_CR27","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/jac\/dkad012","volume":"78","author":"MY Pi","year":"2023","unstructured":"Pi MY, Cai CJ, Zuo LY, et al. Population pharmacokinetics and limited sampling strategies of polymyxin B in critically ill patients. J Antimicrob Chemother. 2023 Mar 2;78(3):792-801.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1488_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2022.106599","volume":"60","author":"P Wang","year":"2022","unstructured":"Wang P, Xing H, Zhang F, et al. Population pharmacokinetics of polymyxin B in critically ill patients receiving continuous venovenous haemofiltration. Int J Antimicrob Agents. 2022 Jul;60(1):106599.","journal-title":"Int J Antimicrob Agents"},{"key":"1488_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106214","volume":"175","author":"X Luo","year":"2022","unstructured":"Luo X, Zhang Y, Liang P, et al. Population pharmacokinetics of polymyxin B and dosage strategy in critically ill patients with\/without continuous renal replacement therapy. Eur J Pharm Sci. 2022 Aug 1;175:106214.","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"1488_CR30","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/cid\/cit334","volume":"57","author":"AM Sandri","year":"2013","unstructured":"Sandri AM, Landersdorfer CB, Jacob J, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis. 2013 Aug;57(4):524-31.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"1488_CR31","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1086\/592577","volume":"47","author":"AP Zavascki","year":"2008","unstructured":"Zavascki AP, Goldani LZ, Cao G, et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis. 2008 Nov 15;47(10):1298-304.","journal-title":"Clin Infect Dis"},{"key":"1488_CR32","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.ijid.2020.08.010","volume":"100","author":"M Moni","year":"2020","unstructured":"Moni M, Sudhir AS, Dipu TS, et al. Clinical efficacy and pharmacokinetics of colistimethate sodium and colistin in critically ill patients in an Indian hospital with high endemic rates of multidrug-resistant Gram-negative bacterial infections: A prospective observational study. Int J Infect Dis. 2020 Nov;100:497-506.","journal-title":"Int J Infect Dis"},{"issue":"12","key":"1488_CR33","doi-asserted-by":"publisher","first-page":"7240","DOI":"10.1128\/AAC.00554-15","volume":"59","author":"I Karaiskos","year":"2015","unstructured":"Karaiskos I, Friberg LE, Pontikis K, et al. Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients. Antimicrob Agents Chemother. 2015 Dec;59(12):7240-8.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"1488_CR34","doi-asserted-by":"publisher","first-page":"4241","DOI":"10.1128\/AAC.06426-11","volume":"56","author":"AF Mohamed","year":"2012","unstructured":"Mohamed AF, Karaiskos I, Plachouras D, et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother. 2012 Aug;56(8):4241-9.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"1488_CR35","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1128\/AAC.01361-08","volume":"53","author":"D Plachouras","year":"2009","unstructured":"Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother. 2009 Aug;53(8):3430-6.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1488_CR36","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.clinthera.2008.01.015","volume":"30","author":"N Markou","year":"2008","unstructured":"Markou N, Markantonis SL, Dimitrakis E, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther. 2008 Jan;30(1):143-51.","journal-title":"Clin Ther"},{"key":"1488_CR37","doi-asserted-by":"crossref","unstructured":"Liang D, Liang Z, Deng G, et al. Population pharmacokinetic analysis and dosing optimization of polymyxin B in critically ill patients. Front Pharmacol. 2023 Mar 29;14:1122310.","DOI":"10.3389\/fphar.2023.1122310"},{"issue":"5","key":"1488_CR38","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/jac\/dkac021","volume":"77","author":"YA Surovoy","year":"2022","unstructured":"Surovoy YA, Burkin MA, Galvidis IA, et al. Comparative polymyxin B pharmacokinetics in patients receiving extracorporeal membrane oxygenation. J Antimicrob Chemother. 2022 Apr 27;77(5):1379-1384.","journal-title":"J Antimicrob Chemother"},{"key":"1488_CR39","doi-asserted-by":"crossref","unstructured":"Ye Q, Wang Q, Chen W, et al. The population pharmacokinetics and dose optimization of polymyxin B in critically ill patients with or without extracorporeal membrane oxygenation. J Clin Pharm Ther. 2022 Oct;47(10):1608-1618.","DOI":"10.1111\/jcpt.13711"},{"issue":"1","key":"1488_CR40","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/jac\/dkw361","volume":"72","author":"S Corcione","year":"2017","unstructured":"Corcione S, Baietto L, Malvasio V, et al. Pharmacokinetics of colistin methanesulfonate (CMS) in burn patients. J Antimicrob Chemother. 2017 Jan;72(1):319-321.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"1488_CR41","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/jac\/dky511","volume":"74","author":"JJ Schmidt","year":"2019","unstructured":"Schmidt JJ, Strunk AK, David S, et al. Single- and multiple-dose pharmacokinetics and total removal of colistin in critically ill patients with acute kidney injury undergoing prolonged intermittent renal replacement therapy. J Antimicrob Chemother. 2019 Apr 1;74(4):997-1002.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"1488_CR42","doi-asserted-by":"publisher","first-page":"407","DOI":"10.4103\/ijmr.IJMR_1464_16","volume":"147","author":"V Gautam","year":"2018","unstructured":"Gautam V, Shafiq N, Mouton JW, et al. Pharmacokinetics of colistin in patients with multidrug-resistant Gram-negative infections: A pilot study. Indian J Med Res. 2018 Apr;147(4):407-412.","journal-title":"Indian J Med Res"},{"issue":"7","key":"1488_CR43","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s00228-013-1493-9","volume":"69","author":"ND Karnik","year":"2013","unstructured":"Karnik ND, Sridharan K, Jadhav SP, et al. Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection. Eur J Clin Pharmacol. 2013 Jul;69(7):1429-36.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"1488_CR44","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1378\/chest.10-0463","volume":"138","author":"R Imberti","year":"2010","unstructured":"Imberti R, Cusato M, Villani P, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest. 2010 Dec;138(6):1333-9.","journal-title":"Chest"},{"issue":"6","key":"1488_CR45","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1093\/jac\/dkg468","volume":"52","author":"J Li","year":"2003","unstructured":"Li J, Coulthard K, Milne R, et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother. 2003 Dec;52(6):987-92.","journal-title":"J Antimicrob Chemother"},{"key":"1488_CR46","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1177\/00912700122010537","volume":"41","author":"MD Reed","year":"2001","unstructured":"Reed MD, Stern RC, O'Riordan MA, et al. The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol. 2001 Jun;41(6):645-54.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1488_CR47","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/FTD.0000000000000572","volume":"41","author":"EJ Kim","year":"2019","unstructured":"Kim EJ, Oh J, Lee K, et al. Pharmacokinetic Characteristics and Limited Sampling Strategies for Therapeutic Drug Monitoring of Colistin in Patients With Multidrug-Resistant Gram-Negative Bacterial Infections. Ther Drug Monit. 2019 Feb;41(1):102-106.","journal-title":"Ther Drug Monit"},{"key":"1488_CR48","doi-asserted-by":"crossref","unstructured":"Fan YX, Chen YC, Li Y, et al. Effects of Different Component Contents of Colistin Methanesulfonate on the Pharmacokinetics of Prodrug and Formed Colistin in Human. Pharm Res. 2021 Jan;38(1):79-87.","DOI":"10.1007\/s11095-021-02991-4"},{"issue":"5","key":"1488_CR49","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.ijantimicag.2017.12.025","volume":"51","author":"M Zhao","year":"2018","unstructured":"Zhao M, Wu XJ, Fan YX, et al. Pharmacokinetics of colistin methanesulfonate (CMS) in healthy Chinese subjects after single and multiple intravenous doses. Int J Antimicrob Agents. 2018 May;51(5):714-720.","journal-title":"Int J Antimicrob Agents"},{"key":"1488_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.754844","volume":"12","author":"P Wang","year":"2021","unstructured":"Wang P, Zhang Q, Feng M, et al. Population Pharmacokinetics of Polymyxin B in Obese Patients for Resistant Gram-Negative Infections. Front Pharmacol. 2021 Nov 22;12:754844.","journal-title":"Front Pharmacol"},{"key":"1488_CR51","doi-asserted-by":"crossref","unstructured":"Miglis C, Rhodes NJ, Avedissian SN, et al. Population Pharmacokinetics of Polymyxin B in Acutely Ill Adult Patients. Antimicrob Agents Chemother. 2018 Feb 23;62(3):e01475-17.","DOI":"10.1128\/AAC.01475-17"},{"key":"1488_CR52","doi-asserted-by":"crossref","unstructured":"Wang P, Zhang Q, Zhu Z, et al. Comparing the Population Pharmacokinetics of and Acute Kidney Injury Due to Polymyxin B in Chinese Patients with or without Renal Insufficiency. Antimicrob Agents Chemother. 2021 Jan 20;65(2):e01900-20.","DOI":"10.1128\/AAC.01900-20"},{"key":"1488_CR53","doi-asserted-by":"crossref","unstructured":"Wang P, Zhang Q, Zhu Z, et al. Population Pharmacokinetics and Limited Sampling Strategy for Therapeutic Drug Monitoring of Polymyxin B in Chinese Patients With Multidrug-Resistant Gram-Negative Bacterial Infections. Front Pharmacol. 2020 Jun 5;11:829.","DOI":"10.3389\/fphar.2020.00829"},{"issue":"4","key":"1488_CR54","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1111\/bcp.14576","volume":"87","author":"XB Yu","year":"2021","unstructured":"Yu XB, Jiao Z, Zhang CH, et al. Population pharmacokinetic and optimization of polymyxin B dosing in adult patients with various renal functions. Br J Clin Pharmacol. 2021 Apr;87(4):1869-1877.","journal-title":"Br J Clin Pharmacol"},{"key":"1488_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.915958","volume":"13","author":"XB Yu","year":"2022","unstructured":"Yu XB, Zhang XS, Wang YX, et al. Population Pharmacokinetics of Colistin Sulfate in Critically Ill Patients: Exposure and Clinical Efficacy. Front Pharmacol. 2022 Jun 16;13:915958.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1488_CR56","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/jac\/dks437","volume":"68","author":"AM Sandri","year":"2013","unstructured":"Sandri AM, Landersdorfer CB, Jacob J, et al. Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. J Antimicrob Chemother. 2013 Mar;68(3):674-7.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"1488_CR57","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1093\/jac\/dkv031","volume":"70","author":"A Jitmuang","year":"2015","unstructured":"Jitmuang A, Nation RL, Koomanachai P, et al. Extracorporeal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: implications for dosing. J Antimicrob Chemother. 2015;70(6):1804-11.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1488_CR58","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1128\/AAC.01741-13","volume":"58","author":"P Koomanachai","year":"2014","unstructured":"Koomanachai P, Landersdorfer CB, Chen G, et al. Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother. 2014;58(1):440-6.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1488_CR59","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/FTD.0000000000000572","volume":"41","author":"EJ Kim","year":"2019","unstructured":"Kim EJ, Oh J, Lee K, et al. Pharmacokinetic Characteristics and Limited Sampling Strategies for Therapeutic Drug Monitoring of Colistin in Patients With Multidrug-Resistant Gram-Negative Bacterial Infections. Ther Drug Monit. 2019 Feb;41(1):102-106.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"1488_CR60","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11095-021-02991-4","volume":"38","author":"YX Fan","year":"2021","unstructured":"Fan YX, Chen YC, Li Y, et al. Effects of Different Component Contents of Colistin Methanesulfonate on the Pharmacokinetics of Prodrug and Formed Colistin in Human. Pharm Res. 2021 Jan;38(1):79-87.","journal-title":"Pharm Res"},{"key":"1488_CR61","doi-asserted-by":"crossref","unstructured":"Fan Y, Li Y, Chen Y, et al. Pharmacokinetics and Pharmacodynamics of Colistin Methanesulfonate in Healthy Chinese Subjects after Multi-Dose Regimen. Antibiotics (Basel). 2022 Jun 14;11(6):798.","DOI":"10.3390\/antibiotics11060798"},{"issue":"6","key":"1488_CR62","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/clpt.2011.48","volume":"89","author":"W Couet","year":"2011","unstructured":"Couet W, Gr\u00e9goire N, Gobin P, et al. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther. 2011 Jun;89(6):875-9.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"1488_CR63","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1185\/03007995.2011.626557","volume":"27","author":"K Mizuyachi","year":"2011","unstructured":"Mizuyachi K, Hara K, Wakamatsu A, et al. Safety and pharmacokinetic evaluation of intravenous colistin methanesulfonate sodium in Japanese healthy male subjects. Curr Med Res Opin. 2011 Dec;27(12):2261-70.","journal-title":"Curr Med Res Opin"},{"key":"1488_CR64","doi-asserted-by":"crossref","unstructured":"Tang T, Li Y, Xu P, et al. Optimization of polymyxin B regimens for the treatment of carbapenem-resistant organism nosocomial pneumonia: a real-world prospective study. Crit Care. 2023 Apr 28;27(1):164.","DOI":"10.1186\/s13054-023-04448-z"},{"key":"1488_CR65","doi-asserted-by":"crossref","unstructured":"Zheng Y, Xu B, Chen S, et al. Population Pharmacokinetic Modeling Using Polymyxin B Free Plasma Concentrations From Published Reports and Evaluation of Dosage Regimens Based on Monte Carlo Simulation in Critically Ill Patients. J Clin Pharmacol. 2023 Sep;63(9):1036-1044.","DOI":"10.1002\/jcph.2261"},{"key":"1488_CR66","doi-asserted-by":"crossref","unstructured":"Galvidis IA, Surovoy YA, Perevoznyuk GS, et al. Unbound serum polymyxin B in patients with sepsis: Detection approaches and limited sampling strategy for clinical practice and research. J Pharm Biomed Anal. 2022 Oct 25;220:114983.","DOI":"10.1016\/j.jpba.2022.114983"},{"issue":"1","key":"1488_CR67","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00228-022-03415-x","volume":"79","author":"YA Surovoy","year":"2023","unstructured":"Surovoy YA, Burkin MA, Galvidis IA, et al. Comparative polymyxin B pharmacokinetics in critically ill patients with renal insufficiency and in continuous veno-venous hemodialysis. Eur J Clin Pharmacol. 2023 Jan;79(1):79-87.","journal-title":"Eur J Clin Pharmacol"},{"key":"1488_CR68","doi-asserted-by":"crossref","unstructured":"Zhang B, Li X, Chen Y, et al. Determination of polymyxin B in human plasma and epithelial lining fluid using LC-MS\/MS and its clinical application in therapeutic drug monitoring. J Pharm Biomed Anal. 2023 Apr 1;227:115291.","DOI":"10.1016\/j.jpba.2023.115291"},{"key":"1488_CR69","doi-asserted-by":"crossref","unstructured":"Li X, Zhang B, Cheng Y, et al. Evaluation and Validation of the Limited Sampling Strategy of Polymyxin B in Patients with Multidrug-Resistant Gram-Negative Infection. Pharmaceutics. 2022 Oct 28;14(11):2323.","DOI":"10.3390\/pharmaceutics14112323"},{"key":"1488_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.975066","volume":"13","author":"Z Yu","year":"2022","unstructured":"Yu Z, Liu X, Du X, et al. Pharmacokinetics\/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae. Front Pharmacol. 2022 Dec 16;13:975066.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1488_CR71","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00228-020-02986-x","volume":"77","author":"W Chen","year":"2021","unstructured":"Chen W, Liu H, Wang Q, et al. Estimation of the area under concentration-time curve of polymyxin B based on limited sampling concentrations in Chinese patients with severe pneumonia. Eur J Clin Pharmacol. 2021 Jan;77(1):95-105.","journal-title":"Eur J Clin Pharmacol"},{"key":"1488_CR72","doi-asserted-by":"crossref","unstructured":"Tam VH, Lee LS, Ng TM, et al. Performance of Population Pharmacokinetic Models in Predicting Polymyxin B Exposures. Microorganisms. 2020 Nov 18;8(11):1814.","DOI":"10.3390\/microorganisms8111814"},{"key":"1488_CR73","doi-asserted-by":"crossref","unstructured":"Manchandani P, Thamlikitkul V, Dubrovskaya Y, et al. Population Pharmacokinetics of Polymyxin B. Clin Pharmacol Ther. 2018 Sep;104(3):534-538.","DOI":"10.1002\/cpt.981"},{"key":"1488_CR74","doi-asserted-by":"crossref","unstructured":"Kubin CJ, Nelson BC, Miglis C, et al. Population Pharmacokinetics of Intravenous Polymyxin B from Clinical Samples. Antimicrob Agents Chemother. 2018 Feb 23;62(3):e01493-17.","DOI":"10.1128\/AAC.01493-17"},{"key":"1488_CR75","doi-asserted-by":"crossref","unstructured":"Thamlikitkul V, Dubrovskaya Y, Manchandani P, et al. Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency. Antimicrob Agents Chemother. 2016 Dec 27;61(1):e01337-16.","DOI":"10.1128\/AAC.01337-16"},{"issue":"11","key":"1488_CR76","doi-asserted-by":"publisher","first-page":"6980","DOI":"10.1128\/AAC.00702-16","volume":"60","author":"P Manchandani","year":"2016","unstructured":"Manchandani P, Dubrovskaya Y, Gao S, et al. Comparative Pharmacokinetic Profiling of Different Polymyxin B Components. Antimicrob Agents Chemother. 2016 Oct 21;60(11):6980-6982.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1488_CR77","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.diagmicrobio.2007.08.008","volume":"60","author":"AL Kwa","year":"2008","unstructured":"Kwa AL, Lim TP, Low JG, et al. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis. 2008 Feb;60(2):163-7.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1488_CR78","doi-asserted-by":"crossref","unstructured":"Li X, Cheng Y, Chen B, et al. Population pharmacokinetics of polymyxin B in patients with liver dysfunction. Br J Clin Pharmacol. 2023 Dec;89(12):3561-3572.","DOI":"10.1111\/bcp.15855"},{"key":"1488_CR79","doi-asserted-by":"crossref","unstructured":"Wang P, Liu D, Sun T, et al. Pharmacokinetics and pharmacodynamics of polymyxin B and proposed dosing regimens in elderly patients with multi-drug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2022 Nov-Dec;60(5-6):106693.","DOI":"10.1016\/j.ijantimicag.2022.106693"},{"key":"1488_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.727170","volume":"12","author":"Y Li","year":"2021","unstructured":"Li Y, Deng Y, Zhu ZY, et al. Population Pharmacokinetics of Polymyxin B and Dosage Optimization in Renal Transplant Patients. Front Pharmacol. 2021 Aug 25;12:727170.","journal-title":"Front Pharmacol"},{"key":"1488_CR81","doi-asserted-by":"crossref","unstructured":"Crass RL, Al Naimi T, Wen B, et al. Pharmacokinetics of Polymyxin B in Hospitalized Adults with Cystic Fibrosis. Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0079221.","DOI":"10.1128\/AAC.00792-21"},{"key":"1488_CR82","doi-asserted-by":"crossref","unstructured":"Avedissian SN, Miglis C, Kubin CJ, et al. Polymyxin B Pharmacokinetics in Adult Cystic Fibrosis Patients. Pharmacotherapy. 2018 Jul;38(7):730-738.","DOI":"10.1002\/phar.2129"},{"key":"1488_CR83","doi-asserted-by":"crossref","unstructured":"Liu X, Chen Y, Yang H, et al. Acute toxicity is a dose-limiting factor for intravenous polymyxin B: A safety and pharmacokinetic study in healthy Chinese subjects. J Infect. 2021 Feb;82(2):207-215.","DOI":"10.1016\/j.jinf.2021.01.006"},{"key":"1488_CR84","doi-asserted-by":"crossref","unstructured":"Wang P, Zhang Q, Zhu Z, et al. Population Pharmacokinetics and Limited Sampling Strategy for Therapeutic Drug Monitoring of Polymyxin B in Chinese Patients With Multidrug-Resistant Gram-Negative Bacterial Infections. Front Pharmacol. 2020 Jun 5;11:829.","DOI":"10.3389\/fphar.2020.00829"},{"issue":"5","key":"1488_CR85","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.coph.2011.07.004","volume":"11","author":"PJ Bergen","year":"2011","unstructured":"Bergen PJ, Li J, Nation RL. Dosing of colistin-back to basic PK\/PD. Curr Opin Pharmacol. 2011 Oct;11(5):464-9.","journal-title":"Curr Opin Pharmacol"},{"key":"1488_CR86","doi-asserted-by":"crossref","unstructured":"Zavascki AP, Nation RL. Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B? Antimicrob Agents Chemother. 2017 Feb 23;61(3):e02319-16.","DOI":"10.1128\/AAC.02319-16"},{"issue":"6","key":"1488_CR87","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/QCO.0000000000000206","volume":"28","author":"SL Parker","year":"2015","unstructured":"Parker SL, Sime FB, Roberts JA. Optimizing dosing of antibiotics in critically ill patients. Curr Opin Infect Dis. 2015;28(6):497\u2013504.","journal-title":"Curr Opin Infect Dis"},{"issue":"8","key":"1488_CR88","doi-asserted-by":"publisher","first-page":"e00583","DOI":"10.1128\/AAC.00583-19","volume":"63","author":"V Pistolesi","year":"2019","unstructured":"Pistolesi V, Morabito S, Di Mario F, et al. A Guide to Understanding Antimicrobial Drug Dosing in Critically Ill Patients on Renal Replacement Therapy. Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00583-19.","journal-title":"Antimicrob Agents Chemother"},{"key":"1488_CR89","doi-asserted-by":"crossref","unstructured":"Almutairy R, Aljrarri W, Noor A, et al. Impact of Colistin Dosing on the Incidence of Nephrotoxicity in a Tertiary Care Hospital in Saudi Arabia. Antibiotics (Basel). 2020 Aug 6;9(8):485.","DOI":"10.3390\/antibiotics9080485"},{"key":"1488_CR90","doi-asserted-by":"crossref","unstructured":"Rychl\u00ed\u010dkov\u00e1 J, Kub\u00ed\u010dkov\u00e1 V, Suk P, et al. Challenges of Colistin Use in ICU and Therapeutic Drug Monitoring: A Literature Review. Antibiotics (Basel). 2023 Feb 22;12(3):437.","DOI":"10.3390\/antibiotics12030437"},{"issue":"10","key":"1488_CR91","doi-asserted-by":"publisher","first-page":"614","DOI":"10.21037\/atm-22-2081","volume":"10","author":"D Peng","year":"2022","unstructured":"Peng D, Zhang F, Lv P, et al. Plasma concentrations of Colistin sulfate in a patient with septic shock on extracorporeal membrane oxygenation and continuous renal replacement therapy: a case report. Ann Transl Med. 2022 May;10(10):614.","journal-title":"Ann Transl Med."},{"issue":"4","key":"1488_CR92","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ijantimicag.2013.06.009","volume":"42","author":"SM Bode-Boger","year":"2013","unstructured":"Bode-B\u00f6ger SM, Schopp B, Tr\u00f6ger U, et al. Intravenous colistin in a patient with serious burns and borderline syndrome: the benefits of therapeutic drug monitoring. Int J Antimicrob Agents. 2013 Oct;42(4):357-60.","journal-title":"Int J Antimicrob Agents"},{"key":"1488_CR93","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2165\/11318100-000000000-00000","volume":"49","author":"MJ Hanley","year":"2010","unstructured":"Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71-87.","journal-title":"Clin Pharmacokinet"},{"key":"1488_CR94","doi-asserted-by":"crossref","unstructured":"Tham KW, Abdul Ghani R, Cua SC, et al. Obesity in South and Southeast Asia-A new consensus on care and management. Obes Rev. 2023 Feb;24(2):e13520.","DOI":"10.1111\/obr.13520"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01488-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01488-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01488-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T08:04:02Z","timestamp":1746777842000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01488-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":94,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1488"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01488-2","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"3 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the Centre of Research Excellence, REduce the burden of antimicrobial reSistance through oPtimal, persONalised Dosing (RESPOND).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jason A. Roberts acknowledges funding from the Australian National Health and Medical Research Council for a Centre of Research Excellence (APP1099452) and a Practitioner Fellowship (APP2007007)\u00a0and an Investigator Grant (APP2009736)\u00a0as well as an Advancing Queensland Clinical Fellowship. Puteri Juanita Zamri, Sazlyna Mohd Sazlly Lim, Fekade Bruck Sime, and Mohd Hafiz Abdul-Aziz have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: PJZ, SMSL, FBS, JAR, MHAA; methodology: PJZ, MHAA; screening and study selection: PJZ, SMSL; data extraction: PJZ, SMSL; writing (original draft preparation); PJZ; writing (review and editing); FBS, JAR, MHAA; supervision: FBS, JAR, MHAA. All authors have read and agreed to the published version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}